Follistatin-344: Clinical Overview and Evidence Limits

Follistatin-344 is sold online as a muscle-building peptide on the strength of follistatin's genuine biology as a myostatin inhibitor. The critical distinction — and the one vendors elide — is that the substantive human research on follistatin involves gene therapy, not injection of the protein.

This guide situates Follistatin-344 within the broader field of peptide therapy and is written for clinicians. It is clinical education, not medical advice, and nothing here should be read as a treatment recommendation or protocol.

What is follistatin?

Follistatin is a naturally occurring glycoprotein that binds and neutralizes members of the TGF-beta superfamily, most relevantly myostatin and the activins. Because myostatin restrains skeletal muscle growth, neutralizing it releases that restraint.

The gene produces isoforms of differing lengths. FST-344 is a precursor isoform; FST-315 is the principal circulating form and FST-288 is largely tissue-bound. Vendor material uses these numbers with more precision than the underlying products warrant.

Follistatin's biology is not confined to muscle. Its name comes from its original identification in ovarian follicular fluid, where it suppresses FSH release — a reminder that this protein participates in reproductive endocrinology as well.

What the human research actually involves

The human follistatin research most often invoked involves AAV-delivered gene therapy — a viral vector carrying the follistatin gene, administered by intramuscular injection, causing the patient's own muscle tissue to produce follistatin continuously and locally. Small early-phase trials have explored this approach in conditions including Becker muscular dystrophy and inclusion body myositis.

That is a fundamentally different intervention from injecting follistatin protein. Gene therapy produces sustained local expression in targeted tissue. An injected protein must survive circulation, distribute, and reach its target — and follistatin is a large glycoprotein with a short circulating half-life and considerable binding in plasma.

There are no adequate human clinical trials establishing that injected follistatin-344 builds muscle, at what dose, or with what safety profile. The credibility of the gene therapy work does not transfer to the injectable product.

Why the safety questions are not theoretical

The myostatin pathway has already produced a documented human safety signal. ACE-031, a decoy receptor blocking the same pathway, had its clinical development halted after causing nosebleeds, gum bleeding and telangiectasias — vascular effects arising because the ligands involved participate in blood vessel regulation, not only muscle.

Follistatin binds broadly across the TGF-beta superfamily, so the same category of concern applies. Its activin binding also raises reproductive endocrine considerations given activin's role in FSH regulation.

The crucial point is that ACE-031's signal was detected because it was in a properly conducted trial with monitoring. Nothing purchased as a research chemical carries that safeguard. A user experiencing a comparable effect would have no framework to attribute it.

Regulatory status

Follistatin-344 is not FDA-approved and is not an established compounding substance. Products sold under the name are unregulated, with no verified identity, purity, or biological activity — and for a large glycoprotein, whether the material retains correct folding and activity at all is a genuine question, not a formality.

The honest patient summary: follistatin is a real regulator of muscle growth, the promising human work is gene therapy that has nothing to do with the product being sold, the pathway has already produced a serious safety signal in trials, and resistance training remains the intervention with actual evidence behind it.